HAEHaemonetics Corporation
$118.73+135% 1Y
$118.73
$47.6752 weeks$119.59
The financials
Haemonetics Corporation by the numbers
Haemonetics Corporation (HAE) reported revenue of $339M in Q1 2027 (quarter ended Jun 27, 2026), up 5.6% from the same quarter a year earlier. That came with a gross margin of 60% and net income of $33M (9.7% of revenue). For the full year FY2026, revenue was $1.33B (−2.0% year on year) and net income $97M. Its largest segment in Q1 2027 was Apheresis at $191M, 56% of the disclosed total, ahead of Med Surg at 44%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q1 2027 | Q1 2026 | Change |
|---|---|---|---|
| Revenue | $339M | $321M | +5.6% |
| Gross profit | $203M | $192M | +5.5% |
| Operating income | $57M | $54M | +6.7% |
| Net income | $33M | $34M | −3.0% |
| Diluted EPS | $0.72 | $0.70 | +2.9% |
| Operating | Revenue | Share |
|---|---|---|
| Apheresis | $191M | 56% |
| Med Surg | $148M | 44% |
Business segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Jun 2026Total $339.4M (-40%)
Med Surg grew +6.0% year on yearApheresis +5.3% year on year
Segment Latestyear on year
- Apheresis$191.3M$191.3Myear on year +5.3%+5.3%
- Med Surg$148.1M$148.1Myear on year +6.0%+6.0%